Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Core Insights - Lyell Immunopharma is advancing its pipeline of next-generation CAR T-cell therapies, specifically focusing on IMPT-314 for aggressive large B-cell lymphoma, which is set to enter pivotal trials [1][2][4] Pipeline Focus - The company is dedicated to developing CAR T-cell therapies that aim to achieve higher response rates and longer durations of response for patients with hematologic malignancies and solid tumors [3] - IMPT-314 is designed to target B-cells expressing either CD19, CD20, or both, utilizing a dual-targeting approach to enhance treatment efficacy compared to existing therapies [4][12] Clinical Data and Development Plans - Initial clinical data from 23 patients indicated an overall response rate of 94% and a complete response rate of 71% in the 3rd-line+ setting, with a median follow-up of 6.3 months [14] - The company plans to initiate pivotal trials for IMPT-314 in the 3rd-line+ setting in 2025 and in the 2nd line by early 2026 [6][17] Financial Outlook - Lyell expects a net cash use of $175 million to$185 million for 2025, which will extend its cash runway into 2027, supporting multiple clinical milestones [9] - The company is streamlining operations and discontinuing the development of LYL119 to focus resources on IMPT-314 and next-generation solid tumor CAR T-cell programs [8] Upcoming Milestones - Additional data from the ongoing Phase 1-2 trial is expected to be presented in mid-2025, including more mature data from the 3rd line+ cohort and initial data from the 2nd line cohort [7] - The first IND application for a new solid tumor CAR T-cell product candidate is anticipated to be submitted in 2026 [8]